Eupraxia Pharmaceuticals Files October 2024 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Oct 2, 2024 · CIK: 1581178
Sentiment: neutral
Topics: filing-update, press-release
TL;DR
Eupraxia Pharma dropped its Oct 2 6-K, check Exhibit 99.1 for news.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 2, 2024, reporting on its activities for the month of October 2024. The filing includes a press release dated October 2, 2024, as Exhibit 99.1. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' ongoing activities and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves as an update and includes a press release, without immediate significant financial or operational disclosures.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- October 2, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4 (location) — Principal executive office address
FAQ
What type of report is Eupraxia Pharmaceuticals Inc. filing?
Eupraxia Pharmaceuticals Inc. is filing a Form 6-K report.
What is the filing date of this Form 6-K?
The Form 6-K was filed on October 2, 2024.
What is included as part of this report?
Exhibit 99.1, a Press Release dated October 2, 2024, is included as part of this report.
Where is Eupraxia Pharmaceuticals Inc.'s principal executive office located?
The company's principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.
Who signed the report on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed the report on behalf of Eupraxia Pharmaceuticals Inc.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-10-02 17:07:09
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 17KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001182.txt ( ) — 62KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: October 2, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer